Abstract This 2022 European Atherosclerosis Society lipoprotein (a)[Lp (a)] consensus
statement updates evidence for the role of Lp (a) in atherosclerotic cardiovascular disease …

High levels of lipoprotein (a)[Lp (a)], an apoB100-containing lipoprotein, are an independent
and causal risk factor for atherosclerotic cardiovascular diseases through mechanisms …

Objective: Lp (a)(lipoprotein [a]) concentrations are associated with atherosclerotic
cardiovascular disease (ASCVD), and new therapies that enable potent and specific …

Lipids are insoluble in water and therefore cholesterol and triglycerides need to be
transported in association with proteins (ie, lipoproteins) in the bloodstream. Lipoproteins …

Abstract Lipoprotein (a)[Lp (a)] is a well-recognized, independent risk factor for
atherosclerotic cardiovascular disease, with elevated levels estimated to be prevalent in …

The 2021 guidelines primary panel selected clinically relevant questions and produced
updated recommendations, on the basis of important new findings that have emerged since …

Cardiovascular disease is the leading cause of death in women and men globally, with most
due to atherosclerotic cardiovascular disease (ASCVD). Despite progress during the last 30 …

Background Atrial fibrillation (AF) is a cardiac arrhythmia associated with an elevated risk of
stroke, heart failure, and mortality. However, preventative therapies are needed with …

Coronary heart disease (CHD) is the leading cause of morbidity and mortality world-wide
and has been characterized as a chronic immunoinflammatory, fibroproliferative disease …

Abstract Lipoprotein (a), Lp (a), is a modified atherogenic low-density lipoprotein particle that
contains apolipoprotein (a). Its levels are highly heritable and variable in the population …